A phase II study of paclitaxel by weekly 1-h infusion for advanced or recurrent esophageal cancer in patients who had previously received platinum-based chemotherapy

PurposeTo evaluate the efficacy and safety of weekly paclitaxel (Taxol®) in patients with advanced or recurrent esophageal cancer.MethodsFifty-three patients with recurrent or advanced esophageal cancer who had previously received platinum-based chemotherapy were treated with paclitaxel 100 mg/m2 once weekly by 1-h infusion on days 1, 8, 15, 22, 29, and 36 of a 49-day cycle. Fifty-two patients were evaluable for efficacy and 53 for safety. Forty-one (77%) patients had recurrent, and 12 (23%) had advanced disease. Most patients (52/53) had squamous cell carcinoma, and one had adenocarcinoma.ResultsA median of 2 cycles was delivered (range 1–8). The overall response rate was 44.2% (23/52; 95% confidence interval (CI) 30.5, 58.7%), with 4 patients (7.7%) achieving complete response. The median duration of response was 4.8 months, and median overall survival was 10.4 months. The most common Grade 3 or 4 adverse events were neutropenia (52.8%), leukopenia (45.3%), anorexia (9.4%), and fatigue (9.4%). Adverse events resulted in treatment discontinuation in 34.0% of patients and dose reductions in 43.4%. There were no treatment-related deaths.ConclusionsWeekly paclitaxel demonstrated efficacy and manageable toxicity in patients with advanced or recurrent esophageal cancer and may be a treatment option for this population.

[1]  Y. Kajiyama,et al.  Radical Lymph Node Dissection for Cancer of the Thoracic Esophagus , 1994, Annals of surgery.

[2]  H. Fujita,et al.  Mortality and Morbidity Rates, Postoperative Course, Quality of Life, and Prognosis After Extended Radical Lymphadenectomy for Esophageal Gancer: Comparison of Three‐Field Lymphadenectomy with Two‐Field Lymphadenectomy , 1993, Annals of surgery.

[3]  M. van Glabbeke,et al.  Phase II trial of vinorelbine in metastatic squamous cell esophageal carcinoma. European Organization for Research and Treatment of Cancer Gastrointestinal Treat Cancer Cooperative Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Jun Horiguchi,et al.  Phase II study of weekly paclitaxel for advanced or metastatic breast cancer in Japan. , 2009, Anticancer research.

[5]  J. Ajani,et al.  Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. , 1994, Journal of the National Cancer Institute.

[6]  Yuquan Wei,et al.  Phase II evaluation of nedaplatin and paclitaxel in patients with metastatic esophageal carcinoma , 2009, Cancer Chemotherapy and Pharmacology.

[7]  J. Ajani,et al.  Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Blot Wj,et al.  The changing epidemiology of esophageal cancer. , 1999, Seminars in oncology.

[9]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[10]  Y. Shimada,et al.  Chemosensitivity of patients with recurrent esophageal cancer receiving perioperative chemotherapy. , 2008, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

[11]  T. Bauknecht,et al.  Phase I study of paclitaxel administered as a 1-hour infusion: toxicity and pharmacokinetics. , 1997, Seminars in oncology.

[12]  A. Jemal,et al.  Cancer Statistics, 2007 , 2007, CA: a cancer journal for clinicians.

[13]  I. Hyodo,et al.  A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  R. Barakat,et al.  Salvage weekly paclitaxel in recurrent ovarian cancer. , 1997, Seminars in oncology.

[15]  J. Fraumeni,et al.  Changing patterns in the incidence of esophageal and gastric carcinoma in the United States , 1998, Cancer.

[16]  S. Natsugoe,et al.  Long‐Term Results of Subtotal Esophagectomy with Three‐Field Lymphadenectomy for Carcinoma of the Thoracic Esophagus , 1994, Annals of surgery.

[17]  P. Philip,et al.  A phase II study of carboplatin and paclitaxel in esophageal cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  V. Moreno,et al.  Time trends incidence of both major histologic types of esophageal carcinomas in selected countries, 1973–1995 , 2002, International journal of cancer.

[19]  H. Watanabe,et al.  Phase II evaluation of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japanese Esophageal Oncology Group Trial. , 1992, Japanese journal of clinical oncology.

[20]  C. Hudis,et al.  Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  L. Leichman,et al.  Paclitaxel given by a weekly 1-h infusion in advanced esophageal cancer. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[23]  Je-Jung Lee,et al.  Bi-weekly Chemotherapy of Paclitaxel and Cisplatin in Patients with Metastatic or Recurrent Esophageal Cancer , 2005, Journal of Korean medical science.

[24]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[25]  L. Norton,et al.  Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[27]  H. Fujita,et al.  Mortality and morbidity rates, postoperative course, quality of life, and prognosis after extended radical lymphadenectomy for esophageal cancer. Comparison of three-field lymphadenectomy with two-field lymphadenectomy. , 1993 .

[28]  K. Yeh,et al.  Concurrent chemoradiotherapy of twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.